

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/24166>

Please be advised that this information was generated on 2017-12-05 and may be subject to change.

## LETTER TO THE EDITORS

## Intraperitoneally Injected Melanin is Highly Uveitogenic

Experimental melanin-protein induced uveitis (EMIU; also called experimental autoimmune anterior uveitis, EAAU) is usually evoked by foot pad immunization of Lewis rats with ocular melanin, in some protocols supported by intraperitoneal injection of additional antigen and pertussis toxin (Broekhuysse et al., 1992a; Chan et al., 1994). EMIU in rats is clinically first recognized as severe anterior uveitis. Choroiditis also develops, and on the long term the disease tends to exhibit multiple spontaneous recurrences (Broekhuysse et al., 1995). The foot pad immunization protocol is used to evoke several types of experimental autoimmune diseases. It has the drawback of the need for Freund's complete adjuvant or Hunter's adjuvant which cause inflammation of the hind foot pads. Various alternatives have been proposed for the avoidance of the use of harmful adjuvants (Claassen and Boersma, 1992; review). In addition, the search for mild protocols reveals the variable pathogenicities of the antigens in rats. They depend on the applied, specific immunization techniques as appears from the latter review, and from the present report. We show that EMIU can efficaciously be induced merely by the intraperitoneal injection of melanin. This method appears to be less successful in the induction of uveitis if specific retinal autoantigens are used.

Purified melanins were isolated from bovine iris and choroid as described previously (Broekhuysse et al., 1993a; 1993b). Briefly, the pigment granules were freed from tissue and tissue debris by homogenization, filtering and sedimentation. They were purified by extraction with 2% sodium dodecyl sulphate (SDS) at 75°C for 10 min, and the resulting SDS-insoluble (SI) fraction was washed with water. The obtained melanin preparations [Iris(m)SI and Chor(m)SI, respectively] were stored at -25°C. The photoreceptor antigens S-antigen and interphotoreceptor retinoid binding protein (IRBP), and the (unpigmented) Triton X-100 soluble bovine retinal pigment epithelial membrane protein (RPE-TS) were prepared from bovine neuro-retina and RPE cells, respectively. Protein determinations, controls for purity by SDS-gel polyacrylamide gel electrophoresis, immunoblotting, and clinical assessment of uveitis were carried out according to Broekhuysse et al. (1986; 1992a; 1992b).

The purified (shortly sonicated) antigens together with 1 or 2 µg pertussis toxin (Sigma, St. Louis, MO, U.S.A.) were intraperitoneally injected in 1.0 ml phosphate buffered salt solution into female Lewis rats of 150–180 g weight. Daily clinical assessment of uveitis started at day 8. EMIU induced by the melanins,

experimental autoimmune pigment epithelial protein-induced uveitis (EAPU), and experimental autoimmune uveitis (EAU) evoked by photoreceptor antigens were scored on a scale of 0–4 as described in the respective literature cited above. The experiments were terminated at a score of 4, or otherwise within 1 week after a maximum score was attained. The eyes were fixed in Bouin solution, and processed according to standard histological techniques.

Table I shows that intraperitoneally injected choroidal and iris melanins are highly pathogenic. All animals developed severe EMIU despite the omission of foot pad immunization with the use of Freund's or Hunter's adjuvant. Coinjection of pertussis toxin is a prerequisite for the development of uveitis. Clinically and histologically, the disease appears identical to EMIU evoked by foot pad immunization with the same dose. The photoreceptor antigens S-antigen and IRBP, and the RPE antigen RPE-TS exhibit low pathogenicity via the intraperitoneal route. High doses (70–200 µg) induce uveitis with a low to moderate incidence, and a mostly moderate intensity. Also in these cases, the inflammatory reactions appear very similar to those evoked by the foot pad immunizations.

In contrast to the latter results, it has been shown that foot pad immunization of Lewis rats with 40–50 µg doses S-antigen or IRBP in Freund's adjuvant even without the use of pertussis toxin efficaciously induces EAU. Together with 1 µg pertussis toxin a dose of only 16 µg or less of the photoreceptor antigens evokes severe EAU with 100% incidence (Gery et al., 1986; Broekhuysse et al., 1986). Similarly, immunization with 75 µg RPE-TS in the foot pads and in addition with 75 µg intraperitoneally induces severe EAPU in all injected rats (Broekhuysse et al., 1992b). Hence, the results in Table I show that ocular melanins have a marked capacity to evoke severe uveitis with high incidence after intraperitoneal injection even at low doses. This efficient immunization might be ascribed to the granular character of the material and the specific location of the pathogen. The uveal melanin granules are usually ball and egg shaped with dimensions between 0.2–1.2 µm, and are coated with the melano-antigen UP-X. They are phagocytized by (peritoneal) macrophages which digest this surface pathogenicity. If the surface protein is completely removed the granules are no longer pathogenic (Broekhuysse et al., 1993b, 1993c). In the immunization protocol described above, melanin granules seem to represent the UP-X antigen's own adjuvant, and the protocol thus provides a mild



TABLE I  
Uveitis evoked in Lewis rats by intraperitoneal antigen injection

| Antigen   | Antigen dose ( $\mu\text{g}$ ) | Ptx* dose ( $\mu\text{g}$ ) | Eyes with uveitis† |      |        | Maximum score‡ | Day of onset‡  |
|-----------|--------------------------------|-----------------------------|--------------------|------|--------|----------------|----------------|
|           |                                |                             | Incidence          | Mild | Severe |                |                |
| Chor(m)SI | 5                              | 1                           | 6/6                | 0    | 6      | 4.0 $\pm$ 0.0  | 13.0 $\pm$ 1.2 |
| Iris(m)SI | 5                              | 1                           | 4/4                | 0    | 4      | 4.0 $\pm$ 0.0  | 11.5 $\pm$ 1.2 |
| Iris(m)SI | 25                             | 0                           | 0/4                | 0    | 0      | 0.0            | —              |
| S-antigen | 70                             | 1                           | 1/6                | 0    | 1      | 3              | 10             |
| IRBP      | 70                             | 1                           | 1/6                | 0    | 1      | 4              | 25             |
| IRBP      | 150                            | 2                           | 4/6                | 2    | 2      | 3.0 $\pm$ 0.6  | 14.0 $\pm$ 2.3 |
| RPE-TS    | 200                            | 2                           | 4/6                | 2    | 2      | 2.5 $\pm$ 0.9  | 11.3 $\pm$ 0.6 |

\* Ptx, pertussis toxin.

† Mild, score 1 and 2; severe, score 3 and 4.

‡ Mean values  $\pm$  s.e.m.

technique to evoke uveitis in rats. The results may also have some implications for our understanding of the uveitogenesis in humans. Involvement of photoreceptor antigens in human autoimmune uveitis has repeatedly been reported (Kijlstra et al., 1990), whereas the role of melanin(-protein) in autoimmune disease is presumed (Broekhuysse et al., 1992a; Chan et al., 1994). The present results make it more likely that melanin(-protein) per se is capable of evoking autoimmune responses as well.

RENÉ M. BROEKHUYSE

HUUB J. WINKENS

ELEONOOR D. KUHLMANN

*Institute of Ophthalmology, University of Nijmegen, 6500 HB Nijmegen, The Netherlands*

## References

- Broekhuysse, R. M., Winkens, H. J. and Kuhlmann, E. D. (1986). Induction of experimental autoimmune uveoretinitis and pinealitis by IRBP. Comparison to uveoretinitis induced by S-antigen and opsin. *Curr. Eye Res.* 5, 231–40.
- Broekhuysse, R. M., Kuhlmann, E. D. and Winkens, H. J. (1992a). Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. *Exp. Eye Res.* 55, 401–11.
- Broekhuysse, R. M., Kuhlmann, E. D. and Winkens, H. J. (1992b). Experimental autoimmune posterior uveitis accompanied by epitheloid cell accumulations (EAPU). A new type of experimental ocular disease induced by immunization with PEP-65, a pigment epithelial polypeptide preparation. *Exp. Eye Res.* 55, 819–29.
- Broekhuysse, R. M. and Kuhlmann, E. D. (1993a). Experimental autoimmune anterior uveitis. The preparation of uveitogenic ocular melanin. *Invest. Ophthalmol. Vis. Sci.* 34, 698–700.
- Broekhuysse, R. M., Kuhlmann, E. D. and Winkens, H. J. (1993b). Experimental autoimmune anterior uveitis (EAAU). III. Induction by immunization with purified uveal and skin melanins. *Exp. Eye Res.* 56, 575–83.
- Broekhuysse, R. M., Kuhlmann, E. D. and Winkens, H. J. (1993c). Experimental autoimmune anterior uveitis (EAAU): induction by melanin antigen and suppression by various treatments. *Pigment Cell Res.* 6, 1–6.
- Broekhuysse, R. M., Kuhlmann, E. D. and Winkens, H. J. (1995). Multiple recurrences in melanin-protein-induced uveitis in the rat. *Ocul. Immunol. Inflamm.*, 3, 149–55.
- Chan, C.-C., Hikita, N., Dastgeib, K., Whitcup, S. M., Gery, J. and Nussenblatt, R. B. (1994). Experimental melanin-protein-induced uveitis in the Lewis rat. *Ophthalmology* 101, 1275–80.
- Claassen, E. and Boersma, W. J. A. (1992). 44th Forum in immunology: characteristics and practical use of new-generation adjuvants as an acceptable alternative to Freund's complete adjuvant. *Res. Immunol.* 143, 475–82.
- Gery, I., Mochizuki, M. and Nussenblatt, R. B. (1986). Retinal specific antigens and the immuno-pathologic process they provoke. *Prog. Retinal Res.* 5, 75–109.
- Kijlstra, A., Hoekzema, R., Van de Lelij, A., Doekes, G. and Rothova, A. (1990). Humoral and cellular immune reactions against retinal antigens in clinical disease. *Curr. Eye Res.* 9 (Suppl.), 85–9.

(Received Cleveland 24 May 1995 and accepted in revised form 26 July 1995)